Early switch with aromatase inhibitors as adjuvant hormonal therapy for postmenopausal breast cancer: Pooled-analysis of 8794 patients

Cancer Treatment Reviews

Volumn 32, Issue 5, 2006, Pages 325-332

  Bria, Emilio ^a   Ciccarese, Mariangela ^a   Giannarelli, Diana ^a   Cuppone, Federica ^a   Nisticò, Cecilia ^a   Nuzzo, Carmen ^a   Natoli, Guido ^a   Fabi, Alessandra ^a   Terzoli, Edmondo ^a   Cognetti, Francesco ^a   Carlini, Paolo ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Adjuvant; Aromatase inhibitors; Breast cancer; Hormonal therapy; Meta analysis; Switch

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DRUG SUBSTITUTION; ENDOMETRIUM CANCER; FRACTURE; HUMAN; MEDICAL LITERATURE; META ANALYSIS; MUSCULOSKELETAL PAIN; OUTCOME ASSESSMENT; POSTMENOPAUSE; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; SURVIVAL ANALYSIS; TAMOXIFEN;

EID: 33746019321     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.04.009     Document Type: Review

References (34)

1. Jemal A., Thomas A., Murray T., et al. Cancer statistics. CA Cancer J Clin 52 (2002) 23-47
2. Fossati R., Confalonieri C., Torri V., et al. Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 1 (1998) 3439-3460
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
4. Smith I.E., and Dowsett M. Aromatase inhibitors in breast cancer. New Engl J Med 348 (2003) 2431-2442
5. Carlini P., Bria E., Giannarelli D., et al. New Aromatase Inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma. Cancer 104 (2005) 1335-1342
6. Nabholtz J.M., Buzdar A., Pollak M., et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18 (2000) 3758-3767
7. Bonneterre J., Thurlimann B.J.K., Robertson J.F.R., et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol 18 (2000) 3748-3757
8. Mouridsen H., Gershanovich M., Sun Y., et al. Superior effi-cacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19 (2001) 2596-2606
9. Mouridsen H., Gershanovich M., Sun Y., et al. Phase III study of Letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21 (2003) 2101-2109
10. Carlini P., Bria E., Ferretti G., et al. New aromatase inhibitors (AIs) as 1st-line endocrine therapy (ET) in metastatic breast cancer (MBC): a pooled analysis of 3238 women from 8 phase III trials. J Clin Oncol 23 (2005) 602 [Meeting Abstracts]
11. Normanno N., Di Maio M., De Maio E., et al. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12 4 (2005) 721-747
12. Ring A., and Dowsett M. Mechanisms of tamoxifen resistance. Endocr-Relat Cancer 11 (2004) 643-658
13. Benz C.C., Scott G.K., Sarup J.C., et al. Estrogen-dependent tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 350 (2003) 1081-1092
14. The ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
15. Thurlimann B., Keshaviah A., Coates A.S., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. New Engl J Med 353 26 (2005) 2747-2757
16. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New Engl J Med 349 (2003) 1793-1802
17. Boccardo F., Rubagotti A., Amoroso D., et al. Sequential tamoxifen and aminoglutetimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian Cooperative Study. J Clin Oncol 19 (2001) 4209-4215
18. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New Engl J Med 350 (2004) 1081-1092
19. Boccardo F., Rubagotti A., Puntoni M., et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian tamoxifen anastrozole (ITA) trial. J Clin Oncol 23 (2005) 1-10
20. Jakesz R., Jonat W., Gnant M., et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366 (2005) 455-462
21. Pignon J.P., and Hill C. Meta-analyses of randomized clinical trials in oncology. Lancet Oncol 2 (2001) 475-482
22. Bria E., Giannarelli D., Felici A., et al. Taxanes with anthracyclines as first line chemotherapy for metastatic breast cancer: pooled analysis of 2805 patients. Cancer 103 4 (2005) 672-679
23. Douglas-Case L., Kimmick G., Paskett E.D., et al. Interpreting measures of treatment effect in cancer clinical trials. The Oncologist 7 (2002) 181-187
24. B Parmar M.K., and Machin D. Survival analysis: a practical approach (1995), John Wiley, Chichester (England)
25. Altman D.G. Confidence intervals for the number needed to treat. BMJ 317 (1998) 1309-1312
26. Boccardo F.M., Rubagotti A., Puntoni M., et al. Switching to anastrozole (ANA) vs continued tamoxifen (TAM) treatment of early breast cancer (EBC). Updated results of the Italian tamoxifen anastrozole (ITA) trial. J Clin Oncol 23 (2005) 526 [Meeting Abstracts]
27. Coombes RC, Hall E, Snowdon CF, et al. The intergroup exemestane study: a randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis. In: Proceedings SABCS 2005. abs. 18.
28. Howell A. ATAC trial update. Lancet 365 (2005) 1225-1226
29. Buzdar A.U., and Cuzick J. Optimum use of aromatase inhibitors in the adjuvant treatment of early breast cancer. J Clin Oncol 23 33 (2005) 8544-8546
30. Punglia R.S., Kuntz K.M., Winter E.P., et al. Optimising adjuvant endocrine therapy in postmenopausal women with early stage breast cancer: a decision analysis. J Clin Oncol 23 22 (2005) 5178-5187
31. Cuzick J., and Howell A. Optimal timing of the use of an aromatase inhibitor in the adjuvant treatment of postmenopausal hormone receptor-positive breast cancer. J Clin Oncol 23 (2005) 658 [Meeting Abstracts]
32. Vakaet A.M.L. Computer modeling is no substitute for randomized clinical trials for decision making in early breast cancer hormonal therapy. J Clin Oncol 23 33 (2005) 8543-8544
33. Jonat W, Gnant M, Boccardo F, et al. Switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-responsive early breast cancer: a meta-analysis of the ARNO 95 Trial, ABCSG Trial 8, and the ITA Trial. In: Proceedings SABCS 2005. abs. 18.
34. Braithwaite R.S., Chlebowski R.T., Lau J., et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18 11 (2003) 937-947